نتایج جستجو برای: ctla 4

تعداد نتایج: 1303680  

Journal: :Journal of immunology 2004
Kwang Woo Hwang William B Sweatt Mona Mashayekhi David A Palucki Hussain Sattar Ellen Chuang Maria-Luisa Alegre

IL-2-deficient mice develop a lymphoproliferative and autoimmune disease characterized by autoimmune hemolytic anemia (AHA) and inflammatory bowel disease. We have previously reported that IL-2 is necessary for optimal up-regulation of CTLA-4, an inducible negative regulator of T cell activation. In this study, we have tested the hypothesis that reduced expression of CTLA-4 in IL-2-deficient T ...

Journal: :Journal of immunology 2004
Gislâine Aparecida Martins Carlos Eduardo Tadokoro Roberta Borges Silva João Santana Silva Luiz Vicente Rizzo

Recent studies have revealed an important role for CTLA-4 as a negative regulator of T cell activation. In the present study, we evaluated the importance of CTLA-4 to the immune response against the intracellular protozoan, Trypanosoma cruzi, the causative agent of Chagas' disease. We observed that the expression of CTLA-4 in spleen cells from naive mice cultured in the presence of live trypoma...

Journal: :PLoS ONE 2008
Helga Schneider Elke Valk Rufina Leung Christopher E. Rudd

The balance of T-cell proliferation, anergy and apoptosis is central to immune function. In this regard, co-receptor CTLA-4 is needed for the induction of anergy and tolerance. One central question concerns the mechanism by which CTLA-4 can induce T-cell non-responsiveness without a concurrent induction of antigen induced cell death (AICD). In this study, we show that CTLA-4 activation of the p...

Journal: :Journal of immunology 2014
Ana Stojanovic Nathalie Fiegler Monika Brunner-Weinzierl Adelheid Cerwenka

NK cells express an array of activating and inhibitory receptors that determine NK cell responses upon triggering by cognate ligands. Although activating NK cell receptors recognize mainly ligands expressed by stressed, virus-infected, or transformed cells, most inhibitory receptors engage MHC class I, preventing NK cell activation in response to healthy cells. In this study, we provide insight...

Journal: :Arthritis & rheumatology 2014
Adam P Cribbs Alan Kennedy Henry Penn Jordan E Read Parisa Amjadi Patricia Green Khaja Syed Szymon W Manka Fionula M Brennan Bernard Gregory Richard O Williams

OBJECTIVE Functionally impaired Treg cells expressing abnormally low levels of CTLA-4 have been well documented in rheumatoid arthritis (RA). However, the molecular defect underlying this reduced expression is unknown. The aims of this study were to assess the role of DNA methylation in regulating CTLA-4 expression in Treg cells isolated from RA patients and to elucidate the mechanism of their ...

Journal: :Arthritis Research & Therapy 2004
Monika C Brunner-Weinzierl Holger Hoff Gerd-R Burmester

Chronic T cell responses, as they occur in rheumatoid arthritis, are complex and are likely to involve many mechanisms. There is a growing body of evidence that, in concert with the T cell antigen receptor signal, CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152) are the primary regulators of T cell responses. Whereas CD28 primarily activates T cell processes, CTLA-4 inhibits them. The ...

2013
Katarzyna Starska Ewa Forma Iwona Lewy-Trenda Jan Woś Paweł Papież Marcin Mochocki Piotr Morawski Renata Kopta Magdalena Bryś

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, CD152) and Foxp3 (forkhead box P3) are receptors present on T cells which play a critical role in the down-regulation of antigen-activated immune responses. To evaluate the potential influences of CTLA-4 and Foxp3 on cancer invasiveness, a case-control study was conducted in 86 patients treated for squamous cell laryngeal carcinoma. The abund...

Journal: :Cancer research 2011
Tihui Fu Qiuming He Padmanee Sharma

The anti-CTL-associated antigen 4 (anti-CTLA-4) antibody ipilimumab is the first agent to show improved survival in a randomized phase III trial that enrolled patients with metastatic melanoma. Studies are ongoing to identify mechanisms that elicit clinical benefit in the setting of anti-CTLA-4 therapy. We previously reported that treated patients had an increase in the frequency of T cells exp...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2009
Hong Chen Chrysoula I Liakou Ashish Kamat Curtis Pettaway John F Ward Derek Ng Tang Jingjing Sun Achim A Jungbluth Patricia Troncoso Christopher Logothetis Padmanee Sharma

Cytotoxic lymphocyte antigen-4 (CTLA-4) blockade is an active immunotherapeutic strategy that is currently in clinical trials in cancer. There are several ongoing trials of anti-CTLA-4 in the metastatic setting of prostate cancer patients with reported clinical responses consisting of decreases in the prostate specific antigen (PSA) tumor marker for some patients. Immunologic markers that corre...

Journal: :Cancer research 2008
Tong Sun Yifeng Zhou Ming Yang Zhibin Hu Wen Tan Xiaohong Han Yuankai Shi Jiarui Yao Yongli Guo Dianke Yu Tian Tian Xiaoyi Zhou Hongbing Shen Dongxin Lin

Antitumor T lymphocytes play a pivotal role in immunosurveillance of malignancy. The CTL antigen 4 (CTLA-4) is a vital negative regulator of T-cell activation and proliferation. This study examined whether genetic polymorphisms in CTLA-4 are associated with cancer susceptibility. A two-stage investigation using haplotype-tagging single nucleotide polymorphism approach and multiple independent c...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید